SCHEMBL1734652

SCHEMBL1734652

C=CCNc1nc(C(N)=O)cc(-c2ccccc2OC)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.46
ADORA1 P30542 4/20 0.45
ADORA2A P29274 2/20 0.45
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
MAPT P10636 5/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HIF1A Q16665 1/20 0.44
ADORA3 P0DMS8 4/20 0.43
CCNT1 O60563 1/20 0.43
CDK9 P50750 1/20 0.43
TP53 P04637 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733597 0.80 TP53 (0.51) VCPMAPTADORA3TP53ALDH1A1
SCHEMBL1734129 0.80 VCP (0.48) VCPADORA1ADORA2AMAPTADORA3
SCHEMBL1734302 0.76 MEN1 (0.51) VCPMAPTMEN1KMT2AHIF1A
SCHEMBL2816888 0.76 HSP90AA1 (0.52) ADORA1ADORA2AMAPTADORA3CCNT1
SCHEMBL1734495 0.73 KDM4E (0.51) ADORA1ADORA2AADORA3CCNT1CDK9
SCHEMBL1734398 0.73 CHRNA7 (0.49) ADORA1ADORA2AMEN1KMT2AADORA3
SCHEMBL1733692 0.73 ADORA3 (0.49) ADORA1ADORA2AADORA3CCNT1CDK9
SCHEMBL1734498 0.73 VCP (0.47) VCPADORA1ADORA2AADORA3CCNT1
SCHEMBL1734511 0.73 KDM4E (0.66) ADORA1ADORA2AMAPTHIF1AADORA3
SCHEMBL1733451 0.72 HPGD (0.61) ADORA1ADORA2AGSK3AGSK3BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 VCP 224/4885ADORA1 142/4885ADORA2A 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.